‘Very, very high conviction’: Sohn fundie’s top stock pick

Eley Griffiths Group portfolio manager David Allingham says the Sohn Hearts & Minds Conference is the Australian investment management industry’s answer to the Woodstock Festival.
David Allingham says Sohn will be a career highlight, and paid tribute to his friend and mentor, the late Brian Eley. Picture: Brook Mitchell

Tom Richardson

‘Very, very high conviction’: Sohn fundie’s top stock pick

November 8, 2021
Eley Griffiths Group portfolio manager David Allingham says the Sohn Hearts & Minds Conference is the Australian investment management industry’s answer to the Woodstock Festival.
Read Transcript

Eley Griffiths Group portfolio manager David Allingham says the Sohn Hearts and Minds Conference is the Australian investment management industry’s answer to the Woodstock Festival.

The former EMI Music employee turned small-cap fundie is buzzing with excitement about presenting at the investment leaders conference on the same stage as Charlie Munger, who co-hosts Berkshire Hathaway’s annual meeting, known as “Woodstock for Capitalists”.

“You know, I’ve been at this game 17 years. I joined Eley Griffiths as a very green, young guy in 2004 who’d come from the music industry, of all places,” Alligham says. “It’s obviously such a great privilege and highlight of my career to be able to take the stage and great to be involved for a cause like medical research.”

GQG Partners

The EGG Small Cap Fund that Allingham runs has returned 11.68 per cent per year since inception, versus 7.34 per cent for its benchmark, the S&P/ASX Small Ords Index, and the fundie is bullish on its stake in GQG Partners, which was 2021’s largest initial public offering.

“We never play IPOs for a stag [profit],” he says. “We don’t think, ‘ah, the book’s hot, everyone’s in it, you know, it’s gonna go up 20 per cent on day one’, that’s not our style. Our style is ‘do the work, have conviction in it and if the stock trades down on day one, fantastic, we’ll buy some more because we know we’re buying it for the three years’.”

Allingham is a massive fan of GQG’s founder Rajiv Jain, who still owns 68.6 per cent of the $5.9 billion fund manager with $US115 billion in funds under management (FUM).

“Look, that business I think did $US21 billion of inflows in FY 2021, the prospectus forecast has them to do $US14 billion in the first half of FY 2022, and only forecasts $3 billion in the second half to June 30,” he says. “So I think those assumptions are very conservative. I think the prospectus FUM they’ve got to close at June next year, they’ll be very close to exceeding that by [this] October.

“It’s a new-age funds management house. He’s got investigative journalists working for him, he’s got people he hires just to tell him where he’s wrong, just doomsdayers.”

According to Allingham, the kicker is GQG has a track record of market-beating performance and management fee structure undercutting its competition in the blue-chip international equities space.

“I think his [Rajiv Jain’s] blended fee rate across the business is 50 basis points. So, I think what he’s got is a cutting-edge fee rate. His retail products are 70 to 75 basis points flat, no performance fees, so he’s got a very low fee rate and exceptional track record.”

Hot sectors and Afterpay

If Allingham could turn back the clock and give himself some advice on his first day at Eley Griffiths 17 years ago, he’d say, “don’t be stubborn”, as it’s one of the great weaknesses in a fund manager, and “learn from mistakes”, as you’re going to make them.

“It’s very tempting to chase momentum in this market,” he says. “But you don’t buy a stock because it’s going up. If you don’t have conviction, and you haven’t done the work, your foundation is never set properly. And therefore, the moment the price action changes against your expectation, you’ll be very vulnerable to just following the price action down.”

The fundie says he’s style-agnostic and sees the merits of both growth and value at different points in the economic cycle.

He’s also “a believer” in today’s market darling, the lithium sector. “From this level you’ve got very good upside in the producers still, with less downside risk should the retail euphoria subside for whatever reason in the coming six to 12 months,” he says.

“I wouldn’t say we’re overweight the sector. We’re kind of market weight. We acknowledge valuations moved aggressively. The pricing is very, very toppy in the spodumene market at the moment, but it may well stay so for a while, so we want to keep an oar in the water there.”

Eley Griffiths’ preference is for lithium miners in production, such as Pilbara Minerals, and Allingham suggests the valuations for popular pre-production players may have run too hot. “The money’s cycled out of, I guess, the more mature producers into the sort of pre-development-phase stocks where there’s clearly more speculation down there,” he says.

One stock he knows more about than pretty much anyone is the buy now, pay later trailblazer Afterpay. In 2017, when Afterpay announced a merger with payments group Touchcorp, the fund manager found itself owning around 9 million shares.

“Don’t even get me started on what the value of that is now,” he exclaims. “Well over a billion dollars, and we initially invested $20 million to $25 million. We rode it to the $40 to $50 range, it went into the ASX 100 so we had to recycle that company.

“That’s probably been the most famous and best investment. And Anthony Eisen and Nick Molnar – if you think about the quality of small-cap management teams, I mean they’d be right up there as the best we’ve ever come across, as a double act.”

After selling Afterpay on the basis that its valuation grew too large for a small-cap fund, Allingham says he looked at the posse of junior buy now, pay later players aiming to copy its success. However, Eley Griffiths passed on them all.

“I think it’s been the right call,” he says. “None of them have done anything. It’s been a bloodbath, to be honest. It’s very, very competitive now, you’re dealing with huge amounts of capital, relatively thin margins.”

Woodstock

While the stock he’s chosen to recommend for Sohn can’t be revealed for now, Allingham exudes a bullish fervour around it.

“It’s one of our highest conviction positions in many years,” he says. “Every stock has its risks; there’s always something to catch you out – that’s the law of small caps. But I think when we frame the outlook for this business on a five-year view, the conviction around it is very, very high. We think calendar 2022 should be a very successful year for the company and there are a couple of catalysts for that value to be recognised in markets.”

The December 3 conference and its fundraising activities for medical research will also be personal for Allingham.

Three years ago, his investment mentor, friend, and Eley Griffiths’ co-founder, Brian Eley, died from motor neurone disease. The high-achieving fund manager says he owes all his success to both Eley and co-founder Ben Griffiths.

“Look, without doubt, the founders of this business have taught me everything I know about markets,” he says. “I think I’ve taken everything from both of those guys and tried to continue to improve and learn. They’ve given me the foundation to run money in small caps.”

This article was originally posted by The AFR here.

Licensed by Copyright Agency. You must not copy this work without permission.

Eley Griffiths Group portfolio manager David Allingham says the Sohn Hearts and Minds Conference is the Australian investment management industry’s answer to the Woodstock Festival.

The former EMI Music employee turned small-cap fundie is buzzing with excitement about presenting at the investment leaders conference on the same stage as Charlie Munger, who co-hosts Berkshire Hathaway’s annual meeting, known as “Woodstock for Capitalists”.

“You know, I’ve been at this game 17 years. I joined Eley Griffiths as a very green, young guy in 2004 who’d come from the music industry, of all places,” Alligham says. “It’s obviously such a great privilege and highlight of my career to be able to take the stage and great to be involved for a cause like medical research.”

GQG Partners

The EGG Small Cap Fund that Allingham runs has returned 11.68 per cent per year since inception, versus 7.34 per cent for its benchmark, the S&P/ASX Small Ords Index, and the fundie is bullish on its stake in GQG Partners, which was 2021’s largest initial public offering.

“We never play IPOs for a stag [profit],” he says. “We don’t think, ‘ah, the book’s hot, everyone’s in it, you know, it’s gonna go up 20 per cent on day one’, that’s not our style. Our style is ‘do the work, have conviction in it and if the stock trades down on day one, fantastic, we’ll buy some more because we know we’re buying it for the three years’.”

Allingham is a massive fan of GQG’s founder Rajiv Jain, who still owns 68.6 per cent of the $5.9 billion fund manager with $US115 billion in funds under management (FUM).

“Look, that business I think did $US21 billion of inflows in FY 2021, the prospectus forecast has them to do $US14 billion in the first half of FY 2022, and only forecasts $3 billion in the second half to June 30,” he says. “So I think those assumptions are very conservative. I think the prospectus FUM they’ve got to close at June next year, they’ll be very close to exceeding that by [this] October.

“It’s a new-age funds management house. He’s got investigative journalists working for him, he’s got people he hires just to tell him where he’s wrong, just doomsdayers.”

According to Allingham, the kicker is GQG has a track record of market-beating performance and management fee structure undercutting its competition in the blue-chip international equities space.

“I think his [Rajiv Jain’s] blended fee rate across the business is 50 basis points. So, I think what he’s got is a cutting-edge fee rate. His retail products are 70 to 75 basis points flat, no performance fees, so he’s got a very low fee rate and exceptional track record.”

Hot sectors and Afterpay

If Allingham could turn back the clock and give himself some advice on his first day at Eley Griffiths 17 years ago, he’d say, “don’t be stubborn”, as it’s one of the great weaknesses in a fund manager, and “learn from mistakes”, as you’re going to make them.

“It’s very tempting to chase momentum in this market,” he says. “But you don’t buy a stock because it’s going up. If you don’t have conviction, and you haven’t done the work, your foundation is never set properly. And therefore, the moment the price action changes against your expectation, you’ll be very vulnerable to just following the price action down.”

The fundie says he’s style-agnostic and sees the merits of both growth and value at different points in the economic cycle.

He’s also “a believer” in today’s market darling, the lithium sector. “From this level you’ve got very good upside in the producers still, with less downside risk should the retail euphoria subside for whatever reason in the coming six to 12 months,” he says.

“I wouldn’t say we’re overweight the sector. We’re kind of market weight. We acknowledge valuations moved aggressively. The pricing is very, very toppy in the spodumene market at the moment, but it may well stay so for a while, so we want to keep an oar in the water there.”

Eley Griffiths’ preference is for lithium miners in production, such as Pilbara Minerals, and Allingham suggests the valuations for popular pre-production players may have run too hot. “The money’s cycled out of, I guess, the more mature producers into the sort of pre-development-phase stocks where there’s clearly more speculation down there,” he says.

One stock he knows more about than pretty much anyone is the buy now, pay later trailblazer Afterpay. In 2017, when Afterpay announced a merger with payments group Touchcorp, the fund manager found itself owning around 9 million shares.

“Don’t even get me started on what the value of that is now,” he exclaims. “Well over a billion dollars, and we initially invested $20 million to $25 million. We rode it to the $40 to $50 range, it went into the ASX 100 so we had to recycle that company.

“That’s probably been the most famous and best investment. And Anthony Eisen and Nick Molnar – if you think about the quality of small-cap management teams, I mean they’d be right up there as the best we’ve ever come across, as a double act.”

After selling Afterpay on the basis that its valuation grew too large for a small-cap fund, Allingham says he looked at the posse of junior buy now, pay later players aiming to copy its success. However, Eley Griffiths passed on them all.

“I think it’s been the right call,” he says. “None of them have done anything. It’s been a bloodbath, to be honest. It’s very, very competitive now, you’re dealing with huge amounts of capital, relatively thin margins.”

Woodstock

While the stock he’s chosen to recommend for Sohn can’t be revealed for now, Allingham exudes a bullish fervour around it.

“It’s one of our highest conviction positions in many years,” he says. “Every stock has its risks; there’s always something to catch you out – that’s the law of small caps. But I think when we frame the outlook for this business on a five-year view, the conviction around it is very, very high. We think calendar 2022 should be a very successful year for the company and there are a couple of catalysts for that value to be recognised in markets.”

The December 3 conference and its fundraising activities for medical research will also be personal for Allingham.

Three years ago, his investment mentor, friend, and Eley Griffiths’ co-founder, Brian Eley, died from motor neurone disease. The high-achieving fund manager says he owes all his success to both Eley and co-founder Ben Griffiths.

“Look, without doubt, the founders of this business have taught me everything I know about markets,” he says. “I think I’ve taken everything from both of those guys and tried to continue to improve and learn. They’ve given me the foundation to run money in small caps.”

This article was originally posted by The AFR here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Australian Financial Review, published on Nov 08, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Mike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/BloombergMike Novogratz, CEO of Galaxy Digital. Photo: Jutharat Pinyodoonyachet/Bloomberg
November 9, 2024

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍Eminence Capital founder Ricky Sandler in Sydney. Picture: John Feder‍
November 6, 2024

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
Vihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie DouvisVihari Ross of Antipodes. Picture: Louie Douvis
November 5, 2024

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
Antipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John FederAntipodes Partners portfolio manager Vihari Ross: ‘We ask where the overvaluation is and where the opportunity is.’ Picture: John Feder
November 5, 2024

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.JO Hambro Asset Management senior portfolio manager Samir Mehta.
November 5, 2024

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.Beeneet Kothari is ready to shock the Sohn Hearts & Minds event.
October 29, 2024

Why this fundie wants you to ‘wince’ at his stock picks

When fund managers come to pitch their favourite stock at the annual Sohn Hearts & Minds conference, there are two ways they can go: they can play it safe, or they can take a risk and shock the room.

Read More
October 27, 2024

IFM Investors’ Rikki Bannan backs small cap investments to rebound after mixed performance

IFM Investors executive director Rikki Bannan believes this year could be a good one to invest in some select small cap stocks.

Read More
October 22, 2024

Meet the 2024 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share eleven new managers for 2024.

Read More
October 21, 2024

Chris Kourtis is on a winning streak. Here’s his next ASX pick

Chris Kourtis of Ellerston Capital thinks he’s found another winner and thinks it’s the last chance to have a bite at the cherry before the strategy plays out.

Read More
Ellerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta CampionEllerston Capital portfolio manager Chris Kourtis. Picture: Britta Campion
October 21, 2024

Why Ellerston Capital’s Chris Kourtis plans to back a ‘hated’ stock

Chris Kourtis of Ellerston Capital plans to tip one of the “most hated” stocks in Australia when he presents at the 2024 Sohn Hearts & Minds Conference.

Read More
 ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion ‘We’re riding a wave which started (with) the first silicon chips,’ Alex Pollak says. Picture: Britta Campion
October 14, 2024

Alex Pollak champions rewards of disruptive investment

Alex Pollak’s funds management company Loftus Peak rode the Nvidia wave and he is now looking at more opportunities in disruptive industry stocks.

Read More
October 8, 2024

Sumit Gautam - Why AI won't deliver in 2025 | Scalar Gauge

Sumit Gautam is the Founder of Scalar Gauge and speaks with Equity Mates ahead of his appearance at the Sohn Hearts & Minds conference.

Read More
September 30, 2024

Missed out on Nvidia and Ozempic? This fundie says it’s never too late

Northcape Capital’s Fleur Wright is still kicking herself for not owning market darlings Nvidia and Novo Nordisk, the maker of the weight loss wonder drug Ozempic, before shares of those companies rocketed in 2023.

Read More
September 23, 2024

Scalar Gauge Fund founder Sumit Gautam cautious about over-hyped AI

Tech investor Sumit Gautam carefully avoids the word bubble when describing the investor frenzy surrounding the rise of artificial intelligence, but warns there are dangers of getting caught up in the hype.

Read More
September 9, 2024

The Wellcome Trust’s Nick Moakes made a 100-year bet. It’s paying off

Chief Investment Officer, Nick Moakes raised almost $3 billion at ultra-low rates. Sometimes the long view can be the most profitable.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.